Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

California Rule Change: Drug Labeling Requirements

Firm Publication

Publications

February 15, 2017

Recently, the California Board of Pharmacy announced changes to its drug labeling rules that will take effect on April 1, 2017. The Board of Pharmacy amended Section 1744 of Article 5 of Division 17 of Title 16 of the California Code of Regulations to require that a pharmacist notify patients, via a written label on the drug container, of the risk associated with any drug that (1) may impair a user's ability to operate a vehicle or vessel, or (2) poses a substantial risk to the person consuming the drug when taken in combination with alcohol.

In addition to identifying certain classes of drug products for which such a label must be included, the amended rule also requires that the pharmacist use his or her professional judgment to determine whether such a label must be included with any other prescription. The previous rule required that the patient be informed of relevant risks, but did not require that written notice of such risks be provided on the label. This updated provision supplements California's existing rules addressing "patient-centered labels" for prescription drugs. 

Pharmacies serving California patients should review their processes to ensure this written notice is included with any such drugs dispensed to a California patient. Should you have any questions, please contact one of the authors listed or any member of our Specialty Pharmacy & Pharmaceuticals team.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.